Trading at 21.27% of 52-week high, DexCom's pendulum swung from euphoria to despair while ROIC hit 6.01%.
This framework sees a business at peak operational efficiency trading at trough valuations — the pendulum has swung too far toward pessimism.
Is the price above or below what the business is worth?
This framework sees clear value despite the negative earnings yield spread. The 92.1% gap to DCF value and below-median historical P/E suggest the market has overcorrected for slowing growth. The implied 6.09% growth rate exceeds current performance but remains reasonable for a healthcare technology leader.
Where is sentiment — at euphoria, despair, or somewhere between?
The pendulum has swung decisively toward despair. When insiders buy aggressively and institutions accumulate while the stock sits at annual lows despite record fundamentals, sentiment has overshot. This is classic pendulum behavior — the disconnect between price and fundamentals signals maximum pessimism.
Where are we in the company's operational cycle?
Multiple operational metrics at peak levels signal late-cycle excellence. When ROIC, margins, and balance sheet efficiency all reach extremes simultaneously, mean reversion becomes probable. The cycle suggests operational metrics have limited upside from here.
Does the upside significantly exceed the downside?
This framework sees compelling asymmetry — nearly 100% upside to intrinsic value with multiple sources of downside protection. The combination of strong cash generation, pricing power, and minimal leverage creates the favorable risk/reward this framework seeks.
This framework sees a textbook pendulum swing — operational excellence meeting market despair. The business has never been stronger (record ROIC, margins, and cash flow) while the valuation has rarely been weaker (21% of 52-week high, 92% below DCF value). When insiders buy $21M and institutions accumulate while retail flees, the asymmetry favors the patient investor. Has the market confused a growth slowdown with business deterioration?
This analysis applies Howard Marks's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Howard Marks. Educational purposes only. Not financial advice.